



Pat. No. 2/12/04 4239-66190 253523
E-143-2002-US

PATENT
Attorney Reference Number 4239-66190

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Martin et al.

Application No. 10/607,598

Filed: June 27, 2003

Confirmation No. 7617

For: METHOD FOR THE TREATMENT OF
MULTIPLE SCLEROSIS

Examiner: Not yet assigned

Art Unit: 1646

Attorney Reference No. 4239-66190

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed February 12, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER


Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and copies of references cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



SAS: 02/12/04 4239-66190 252524

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Martin et al.

Application No. 10/607,598

Filed: June 27, 2003

Confirmation No. 7617

For: METHOD FOR THE TREATMENT OF
MULTIPLE SCLEROSIS

Examiner: Not yet assigned

Art Unit: 1646

Attorney Reference No. 4239-66190

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed February 12, 2004

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Also enclosed is the English abstract of WO 92/13886, which was published in French. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal sheet for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66190
Application Number	10/607,598
Filing Date	June 27, 2003
First Named Inventor	Martin
Art Unit	1646
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,530,101	06/25/1996	Queen et al.
		5,585,089	12/17/1996	Queen et al.
		5,620,686	04/15/1997	Mason
		5,693,762	12/02/1997	Queen et al.
		6,013,256	01/11/2001	Light et al.
		6,096,728	01/08/2001	Collins et al.
		6,180,370	01/30/2001	Queen et al.
		6,346,247	02/12/2002	Stafford et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 89/09622	10/19/1989	WIPO
		WO 90/07861	07/26/1990	WIPO
		WO 92/13886	08/20/1992	WIPO
		WO 93/01289	01/21/1993	WIPO
		WO 00/25816	05/11/2000	WIPO

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66190
Application Number	10/607,598
Filing Date	June 27, 2003
First Named Inventor	Martin
Art Unit	1646
Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		"Advances in Basic and Clinical Research on MS Reported at AAN," www.nationalmssociety.org/Research-2003Apr15.asp , April 15, 2003.
		Bellamy et al., "The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes," <i>Clin. Exp. Immunol.</i> 61: 248-256, 1985.
		Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival," <i>Proc. Natl. Acad. Sci. USA</i> 88: 2663-2667, 1991.
		Church, A., "Clinical advances in therapies targeting the interleukin-2 receptor," <i>Q J Med</i> 96: 91-102, 2003.
		Giorelli et al., "IFN- β 1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms," <i>Journal of Interferon and Cytokine Research</i> 21: 809-812, 2001.
		Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders," <i>Cancer Res.</i> 50(5): 1495-1502, 1990.
		Khoury et al., "Changes in Activated T Cells in the Blood Correlate with Disease Activity in Multiple Sclerosis," <i>Arch. Neurol</i> 57: 1183-1189, 2000.
		Lee et al., "Spatial mapping of T ₂ and gadolinium-enhancing T ₁ lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?" <i>Brain</i> 122: 1261-1270, 1999.
		Lehky et al., "Reduction in HTLV-I Proviral Load and Spontaneous Lymphoproliferation in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients Treated with Humanized Anti-Tac," <i>Annals of Neurology</i> 44: 942-947, 1998.
		Marwick, C., "Scientists Recall Progress and Promise of Translational Research," <i>J. Natl. Cancer Inst.</i> 93: 13-15, 2001.
		"Monoclonal antibodies with clinical indications," www.imgt.cines.fr:8104/textes/IMGTrepertoire/GenesClinical/monoclonalantibodies , May 19, 2003.
		Nussenblatt et al., "Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial," <i>Proc. Natl. Acad. Sci. USA</i> 96 (13): 7462-7466, 1999.
		Package insert for Rebif (interferon beta-1a), November 6, 2002.

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66190
		Application Number	10/607,598
		Filing Date	June 27, 2003
		First Named Inventor	Martin
		Art Unit	1646
		Examiner Name	Not yet assigned
		Package insert for Zenapax (Daclizumab), December 1997.	
		Paty et al., "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis," <i>Neurology</i> 43:662-667	
		Posey et al., "TCP presents its annual list of drugs in development and what their approval will mean to long-term care patients," www.ascp.com/public/pubs/tcp/1997/apr/newdrugs.html , June 4, 2002.	
		Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. USA</i> 86 (24): 10029-10033, 1989.	
		Samkoff, Lawrence, "Multiple Sclerosis: Update of Treatment," <i>Hospital Physician</i> pp. 21-27, 2002.	
		"Study of Zenapax in the treatment of multiple sclerosis," www.mult.sclerosis.org/news/Nov2000/ZenapaxMS.html , November 27, 2000.	
		Waldmann, et al., "Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy," <i>Hematology</i> (1): 394, 2000.	
		Wandinger et al., "Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes," <i>Ann. Neurol.</i> , 50(3):349-57 (2001).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	